Aliases & Classifications for Paronychia

MalaCards integrated aliases for Paronychia:

Name: Paronychia 12 74 54 43 15 17
Paronychia Inflammation 12 71
Onychia and Paronychia of Finger 12
Onychia and Paronychia of Toe 12
Fungal Nail Infection 12
Infected Nailfold 12
Onychomycosis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13117
MeSH 43 D010304
NCIt 49 C79702
SNOMED-CT 67 71906005
ICD10 32 L03.0
UMLS 71 C0030578 C0040261

Summaries for Paronychia

Disease Ontology : 12 A nail disease characterized by often-tender bacterial or fungal hand infection or foot infection due to either bacteria or fungus (Candida albicans) where the nail and skin meet at the side or the base of a finger or toe nail. The infection can start suddenly (acute paronychia) or gradually (chronic paronychia). Puss is usually present, along with gradual thickening and browning discoloration of the nail plate.

MalaCards based summary : Paronychia, also known as paronychia inflammation, is related to melanoma and leukemia. An important gene associated with Paronychia is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cetuximab and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Paronychia is a nail disease that is an often tender bacterial or fungal infection of the hand or foot,... more...

Related Diseases for Paronychia

Diseases related to Paronychia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 melanoma 29.1 MTOR KRAS HRAS ERBB4 ERBB2 EGFR
2 leukemia 29.0 KRAS HRAS ERBB4 ERBB3 ERBB2
3 adenocarcinoma 28.8 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
4 exanthem 28.0 MTOR MAP2K7 KRAS HRAS ERBB2 EGFR
5 lung cancer susceptibility 3 27.8 SERPINA3 MTOR MAP2K7 KRAS HRAS ERBB4
6 candidal paronychia 12.4
7 neuropathy, hereditary sensory and autonomic, type iia 11.3
8 pyogenic granuloma 10.4
9 vaginal adenosarcoma 10.4 MTOR ERBB4
10 vaginal carcinosarcoma 10.4 MTOR ERBB4
11 pemphigus 10.4
12 nail disorder, nonsyndromic congenital, 10 10.4
13 contact dermatitis 10.4
14 syringocystadenoma papilliferum 10.4 SERPINA3 KRAS
15 pemphigus vulgaris, familial 10.4
16 signet ring basal cell carcinoma 10.4 KRAS HRAS
17 trachea carcinoma in situ 10.3 KRAS HRAS
18 adenosquamous lung carcinoma 10.3 KRAS EGFR
19 nasal cavity adenocarcinoma 10.3 KRAS HRAS
20 hepatoid adenocarcinoma 10.3 SERPINA3 EGFR
21 ampulla of vater neoplasm 10.3 KRAS HRAS
22 periampullary adenoma 10.3 KRAS HRAS
23 recurrent respiratory papillomatosis 10.3 ERBB2 EGFR
24 eccrine papillary adenoma 10.3 KRAS HRAS
25 breast scirrhous carcinoma 10.3 ERBB2 EGFR
26 papillary adenoma 10.3 KRAS HRAS
27 myh-associated polyposis 10.3 KRAS HRAS
28 appendix adenocarcinoma 10.3 KRAS HRAS
29 kala-azar 1 10.3
30 leishmaniasis 10.3
31 wolffian duct adenocarcinoma 10.3 KRAS HRAS
32 papillary squamous carcinoma 10.3 ERBB3 EGFR
33 breast metaplastic carcinoma 10.3 ERBB2 EGFR
34 pancreatic intraductal papillary-mucinous neoplasm 10.3 KRAS HRAS
35 non-proliferative fibrocystic change of the breast 10.3 SERPINA3 ERBB2
36 ascending colon cancer 10.3 KRAS HRAS
37 biliary tract benign neoplasm 10.3 KRAS HRAS
38 schimmelpenning-feuerstein-mims syndrome 10.3 KRAS HRAS
39 ovarian mucinous neoplasm 10.3 KRAS HRAS
40 tumor of exocrine pancreas 10.3 KRAS HRAS
41 squamous cell carcinoma 10.3
42 dermatitis 10.3
43 cutaneous leishmaniasis 10.3
44 pulmonic stenosis 10.2 KRAS HRAS
45 her2-receptor positive breast cancer 10.2 ERBB4 ERBB2
46 appendix disease 10.2 KRAS HRAS
47 small intestine adenocarcinoma 10.2 KRAS HRAS
48 progesterone-receptor negative breast cancer 10.2 ERBB2 EGFR
49 breast squamous cell carcinoma 10.2 HRAS ERBB2
50 chordoma 10.2 SERPINA3 MTOR EGFR

Graphical network of the top 20 diseases related to Paronychia:



Diseases related to Paronychia

Symptoms & Phenotypes for Paronychia

GenomeRNAi Phenotypes related to Paronychia according to GeneCards Suite gene sharing:

26 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.46 MTOR HRAS KRAS AURKA EGFR
2 Decreased viability GR00106-A-0 11.46 ERBB3 KRAS
3 Decreased viability GR00221-A-1 11.46 MTOR HRAS KRAS AURKA MAP2K7 EGFR
4 Decreased viability GR00221-A-2 11.46 ERBB3 MAP3K8 HRAS KRAS AURKA
5 Decreased viability GR00221-A-3 11.46 MAP3K8 ERBB2 HRAS WNK1
6 Decreased viability GR00221-A-4 11.46 ERBB3 MAP3K8 MTOR ERBB2 WNK1 AURKA
7 Decreased viability GR00231-A 11.46 AURKA
8 Decreased viability GR00301-A 11.46 ERBB3 MAP3K8 ERBB4 KRAS
9 Decreased viability GR00342-S-1 11.46 MAP3K8 MTOR ERBB4 MAP2K7
10 Decreased viability GR00342-S-2 11.46 ERBB3 MAP3K8 MTOR
11 Decreased viability GR00342-S-3 11.46 ERBB3 MAP3K8
12 Decreased viability GR00381-A-1 11.46 KRAS
13 Decreased viability GR00402-S-2 11.46 ERBB3 MAP3K8 MTOR ERBB2 HRAS WNK1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.45 KRAS MTOR
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.45 ERBB3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.45 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.45 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.45 KRAS
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.45 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.45 ERBB3 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.45 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.45 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.45 KRAS WNK1
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.45 ERBB3 KRAS MTOR WNK1
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.45 KRAS
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.45 WNK1
27 Decreased substrate adherent cell growth GR00193-A-1 10.2 AURKA ERBB3
28 Decreased substrate adherent cell growth GR00193-A-2 10.2 AURKA EGFR ERBB3 MAP2K7 MAP3K8 MTOR
29 Decreased substrate adherent cell growth GR00193-A-3 10.2 MAP2K7 WNK1
30 Decreased viability with paclitaxel GR00179-A-1 10.14 EGFR MTOR ERBB2
31 Decreased viability with paclitaxel GR00179-A-2 10.14 MTOR
32 Decreased viability with paclitaxel GR00179-A-3 10.14 EGFR MTOR
33 Decreased cell migration GR00055-A-1 10 AURKA EGFR ERBB4 HRAS KRAS MTOR
34 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.97 EGFR ERBB2 ERBB4 HRAS MAP3K8 MTOR
35 Increased cell death HMECs cells GR00103-A-0 9.85 AURKA EGFR ERBB3 ERBB4 MAP3K8 WNK1
36 Decreased cell proliferation GR00353-A 9.81 AURKA ERBB2 MTOR WNK1
37 Increased cell migration GR00055-A-3 9.8 AURKA EGFR ERBB4 HRAS KRAS MTOR
38 Increased cell viability after pRB stimulation GR00230-A-1 9.65 AURKA EGFR ERBB2 ERBB3 ERBB4
39 Increased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.55 AURKA ERBB3 ERBB4 MAP2K7 MTOR
40 Reduced mammosphere formation GR00396-S 9.43 EGFR ERBB3 HRAS KRAS MAP3K8 MTOR
41 Transferrin accumulation in the perinuclear area GR00356-A-3 8.8 AURKA MTOR WNK1

MGI Mouse Phenotypes related to Paronychia:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 CDAN1 EGFR ERBB2 ERBB3 ERBB4 HRAS
2 behavior/neurological MP:0005386 10.18 CDAN1 ERBB2 ERBB3 ERBB4 HRAS KRAS
3 cellular MP:0005384 10.15 AURKA EGFR ERBB2 ERBB3 ERBB4 KRAS
4 mortality/aging MP:0010768 10.15 AURKA CDAN1 EGFR ERBB2 ERBB3 ERBB4
5 embryo MP:0005380 10.13 AURKA CDAN1 EGFR ERBB2 ERBB3 ERBB4
6 growth/size/body region MP:0005378 10.13 AURKA CDAN1 EGFR ERBB2 ERBB3 HRAS
7 endocrine/exocrine gland MP:0005379 10.11 CDAN1 EGFR ERBB2 ERBB3 ERBB4 HRAS
8 integument MP:0010771 9.95 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS
9 muscle MP:0005369 9.87 EGFR ERBB2 ERBB3 ERBB4 KRAS MTOR
10 neoplasm MP:0002006 9.86 AURKA EGFR ERBB2 ERBB3 HRAS KRAS
11 nervous system MP:0003631 9.81 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS
12 normal MP:0002873 9.61 CDAN1 EGFR ERBB2 ERBB3 ERBB4 HRAS
13 respiratory system MP:0005388 9.17 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS

Drugs & Therapeutics for Paronychia

Drugs for Paronychia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
2
Irinotecan Approved, Investigational Phase 4 100286-90-6, 97682-44-5 60838
3
leucovorin Approved Phase 4 58-05-9 6006 143
4
Fluorouracil Approved Phase 4 51-21-8 3385
5
Phylloquinone Approved, Investigational Phase 4 84-80-0
6
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
7
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
8
Amorolfine Approved, Investigational Phase 4 78613-35-1
9
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
10
Tavaborole Approved, Investigational Phase 4 174671-46-6
11
Bifonazole Approved, Investigational Phase 4 60628-96-8 2378
12
carbamide peroxide Approved Phase 4 124-43-6
13
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
14
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
15
Efinaconazole Approved Phase 4 164650-44-6
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
18
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
19 Menaquinone Investigational Phase 4 1182-68-9
20 Keratolytic Agents Phase 4
21 Antibodies, Monoclonal Phase 4
22 Antineoplastic Agents, Immunological Phase 4
23 Vitamins Phase 4
24 Vitamin B Complex Phase 4
25 Vitamin B9 Phase 4
26 Folate Phase 4
27 naphthoquinone Phase 4
28 Antibodies Phase 4
29 Immunoglobulins Phase 4
30 Vitamin K 1 Phase 4
31 Vitamin K Phase 4
32 Trace Elements Phase 4
33 Micronutrients Phase 4
34 Vitamin B3 Phase 4
35 Nutrients Phase 4
36 Nicotinic Acids Phase 4
37 Pharmaceutical Solutions Phase 4
38 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
39 Anti-Bacterial Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Antiprotozoal Agents Phase 4
42 Protective Agents Phase 4
43 Free Radical Scavengers Phase 4
44 Liposomal amphotericin B Phase 4
45 Antioxidants Phase 4
46
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
47
Luliconazole Approved Phase 2, Phase 3 187164-19-8
48
Econazole Approved Phase 2 27220-47-9 3198
49 Tomato Approved Phase 2
50 Lycopene Approved, Investigational Phase 2 502-65-8 53477748

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
2 A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
3 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
4 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
5 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
6 Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
7 A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
8 A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails Completed NCT02812771 Phase 4 Efinaconazole
9 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
10 Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
11 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
12 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
13 Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
14 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
15 An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
16 Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
17 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
18 A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Active, not recruiting NCT03280927 Phase 4 Jublia®
19 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
20 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
21 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Unknown status NCT03171584 Phase 3 Terbinafine
22 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
23 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
24 Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis Completed NCT02547701 Phase 3 P-3058
25 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
26 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
27 Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
28 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
29 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
30 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
31 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
32 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
33 A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
34 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Completed NCT03168841 Phase 3 Efinaconazole Topical
35 A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
36 Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis) Completed NCT00935649 Phase 2, Phase 3
37 A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
38 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
39 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
40 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks Terminated NCT01208129 Phase 3 NAB001;Placebo control
41 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
42 Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study Unknown status NCT00771732 Phase 2
43 A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail Unknown status NCT00385502 Phase 2 EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
44 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
45 AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE Unknown status NCT01528813 Phase 2 Amorolfine lacquer
46 Double-blind, Phase II Study to Assess the Effectiveness of Lycopene vs Placebo to Reduce Skin Toxicity in Patients With Colorectal Carcinoma Treated With Panitumumab Unknown status NCT03167268 Phase 2 Lycopene
47 Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
48 An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) Completed NCT01814020 Phase 2 MOB015B
49 A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients Completed NCT03207906 Phase 2 VBP-926
50 An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis Completed NCT00680160 Phase 2 AN2690

Search NIH Clinical Center for Paronychia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ciclopirox
Ciclopirox olamine
Itraconazole
tavaborole
terbinafine
Terbinafine hydrochloride

Cochrane evidence based reviews: paronychia

Genetic Tests for Paronychia

Anatomical Context for Paronychia

MalaCards organs/tissues related to Paronychia:

40
Skin, Lung, Testes, Bone, Breast, Colon, T Cells

Publications for Paronychia

Articles related to Paronychia:

(show top 50) (show all 979)
# Title Authors PMID Year
1
[Topical steroids in the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab]. 61 54
20417368 2010
2
Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. 54 61
20103661 2010
3
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. 61 54
19689244 2009
4
[Cutaneous toxicities]. 61 54
18931563 2008
5
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. 54 61
17147969 2007
6
The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. 61 54
16965448 2006
7
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. 54 61
16844529 2006
8
Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. 61 54
16403122 2006
9
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. 54 61
16012181 2005
10
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. 61 54
14571080 2003
11
Paronychia argentea Lam. protects renal endothelial cells against oxidative injury. 61
31629861 2020
12
Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. 61
30832554 2020
13
A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. 61
31397829 2019
14
Nail apparatus squamous cell carcinoma mimicking paronychia. 61
31502299 2019
15
[Chronic paronychia and Candida: A descriptive and analytical study of 164 cases]. 61
31839272 2019
16
A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia. 61
31240513 2019
17
Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. 61
31763692 2019
18
Group A Streptococcal Paronychia and Blistering Distal Dactylitis in Children: Diagnostic Accuracy of a Rapid Diagnostic Test and Efficacy of Antibiotic Treatment. 61
31782958 2019
19
Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient. 61
31705590 2019
20
Nail Involvement during Pemphigus. 61
31799264 2019
21
Squamous cell carcinoma of the nail bed: A case report. 61
31750342 2019
22
Ungual Tuberculosis: A Unique Clinical Case. 61
31799269 2019
23
Fungal melanonychia caused by Candida parapsilosis successfully treated with oral fosravuconazole. 61
31342551 2019
24
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab. 61
31641845 2019
25
Allium sativum Extract Chemical Composition, Antioxidant Activity and Antifungal Effect against Meyerozyma guilliermondii and Rhodotorula mucilaginosa Causing Onychomycosis. 61
31683743 2019
26
Techniques for Continuous Irrigation of Septic Joints of the Hand. 61
30973488 2019
27
Retronychia of the toenails: a review with emphasis on pathogenesis, new diagnostic and management trends. 61
31076847 2019
28
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). 61
31446992 2019
29
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. 61
31265163 2019
30
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. 61
31807143 2019
31
Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. 61
31264159 2019
32
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study. 61
31010330 2019
33
Management and Outcome of Taxane-Induced Nail Side Effects: Experience of 79 Patients from a Single Centre. 61
31559250 2019
34
Adverse cutaneous effects of neratinib. 61
30321080 2019
35
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. 61
31319994 2019
36
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. 61
30045682 2019
37
Osimertinib in Patients with T790M Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. 61
31345012 2019
38
Nail Changes in Sézary Syndrome: A Single-Center Study and Review of the Literature. 61
30917680 2019
39
Are topical beta-blockers really effective "in real life" for targeted therapy-induced paronychia. 61
30847700 2019
40
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. 61
31069718 2019
41
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. 61
31095895 2019
42
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. 61
31089973 2019
43
Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases. 61
31149566 2019
44
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. 61
31126331 2019
45
Prevalence of Community-Acquired Pyoderma in Dermatological Outpatient Department of a Tertiary Care Hospital. 61
31477954 2019
46
Occupational Retronychia: A Report of a Case in a UPS Employee. 61
31049341 2019
47
Atypical acute paronychia. 61
31106770 2019
48
Papulopustules and paronychia in a lung carcinoma. 61
30297249 2019
49
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. 61
29898592 2019
50
Development of Periungual Pyogenic Granuloma with Associated Paronychia Following Isotretinoin Therapy: A Case Report and a Review of the Literature. 61
31119008 2019

Variations for Paronychia

Expression for Paronychia

Search GEO for disease gene expression data for Paronychia.

Pathways for Paronychia

Pathways related to Paronychia according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 SERPINA3 MTOR MAP3K8 MAP2K7 KRAS HRAS
2
Show member pathways
13.81 WNK1 MTOR MAP3K8 MAP2K7 KRAS HRAS
3
Show member pathways
13.71 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
4
Show member pathways
13.68 MAP2K7 KRAS HRAS ERBB4 ERBB3 ERBB2
5
Show member pathways
13.67 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
6
Show member pathways
13.55 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
7
Show member pathways
13.54 MTOR MAP3K8 MAP2K7 KRAS HRAS ERBB4
8
Show member pathways
13.44 MTOR MAP3K8 KRAS HRAS ERBB4 ERBB3
9
Show member pathways
13.41 WNK1 MTOR MAP3K8 KRAS HRAS ERBB4
10
Show member pathways
13.37 MAP3K8 KRAS HRAS ERBB4 ERBB3 ERBB2
11
Show member pathways
13.32 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
12
Show member pathways
13.28 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
13
Show member pathways
13.22 MTOR MAP3K8 MAP2K7 KRAS HRAS ERBB4
14
Show member pathways
13.1 MAP3K8 MAP2K7 KRAS HRAS EGFR
15
Show member pathways
13.1 MTOR ERBB4 ERBB3 ERBB2 EGFR
16
Show member pathways
13.02 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
17
Show member pathways
12.98 MTOR MAP3K8 MAP2K7 KRAS HRAS EGFR
18
Show member pathways
12.94 MTOR MAP2K7 KRAS HRAS EGFR
19
Show member pathways
12.92 MTOR KRAS HRAS ERBB3 ERBB2 EGFR
20
Show member pathways
12.91 MAP2K7 KRAS HRAS ERBB2 EGFR
21
Show member pathways
12.88 MTOR KRAS HRAS ERBB2 EGFR
22 12.86 MTOR KRAS HRAS ERBB2 EGFR
23
Show member pathways
12.79 MTOR KRAS HRAS ERBB2 EGFR
24
Show member pathways
12.77 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
25
Show member pathways
12.75 MTOR MAP2K7 KRAS HRAS ERBB3 ERBB2
26 12.73 MAP3K8 MAP2K7 KRAS HRAS ERBB4 ERBB3
27
Show member pathways
12.7 MTOR MAP2K7 KRAS HRAS EGFR
28
Show member pathways
12.7 MTOR MAP2K7 KRAS HRAS ERBB3 ERBB2
29
Show member pathways
12.69 MAP3K8 MAP2K7 KRAS HRAS EGFR
30
Show member pathways
12.67 MTOR MAP2K7 KRAS HRAS EGFR
31
Show member pathways
12.66 MTOR MAP3K8 MAP2K7 KRAS HRAS EGFR
32
Show member pathways
12.65 MTOR MAP3K8 MAP2K7 KRAS HRAS ERBB4
33
Show member pathways
12.59 KRAS HRAS ERBB2 EGFR
34 12.59 MTOR KRAS HRAS ERBB3 ERBB2 EGFR
35
Show member pathways
12.53 MTOR MAP3K8 MAP2K7 HRAS
36
Show member pathways
12.53 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
37
Show member pathways
12.5 MTOR KRAS HRAS ERBB2
38
Show member pathways
12.48 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
39
Show member pathways
12.44 MTOR MAP2K7 KRAS HRAS
40
Show member pathways
12.44 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
41
Show member pathways
12.43 MAP2K7 KRAS HRAS EGFR
42
Show member pathways
12.43 MTOR KRAS HRAS EGFR
43
Show member pathways
12.39 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
44
Show member pathways
12.35 HRAS ERBB3 ERBB2 EGFR
45
Show member pathways
12.35 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
46
Show member pathways
12.32 ERBB4 ERBB3 ERBB2 EGFR
47
Show member pathways
12.28 MAP2K7 KRAS HRAS EGFR
48
Show member pathways
12.26 MTOR MAP2K7 KRAS HRAS
49 12.26 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
50 12.23 MTOR KRAS HRAS ERBB2 EGFR AURKA

GO Terms for Paronychia

Cellular components related to Paronychia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.96 WNK1 MTOR MAP3K8 MAP2K7 KRAS HRAS
2 receptor complex GO:0043235 9.46 ERBB4 ERBB3 ERBB2 EGFR
3 basolateral plasma membrane GO:0016323 9.26 ERBB4 ERBB3 ERBB2 EGFR
4 basal plasma membrane GO:0009925 8.92 ERBB4 ERBB3 ERBB2 EGFR

Biological processes related to Paronychia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.15 MAP3K8 MAP2K7 KRAS HRAS ERBB4 ERBB3
2 positive regulation of cell proliferation GO:0008284 9.99 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
3 positive regulation of gene expression GO:0010628 9.96 MTOR KRAS HRAS ERBB3 ERBB2
4 MAPK cascade GO:0000165 9.88 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 MAP2K7 HRAS ERBB4 EGFR
6 positive regulation of protein kinase B signaling GO:0051897 9.85 MTOR ERBB4 ERBB3 ERBB2 EGFR
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 ERBB4 ERBB3 ERBB2 EGFR
8 peptidyl-tyrosine phosphorylation GO:0018108 9.83 MAP2K7 ERBB4 ERBB3 ERBB2 EGFR
9 wound healing GO:0042060 9.8 MTOR ERBB3 ERBB2 EGFR
10 positive regulation of MAP kinase activity GO:0043406 9.78 KRAS HRAS ERBB2 EGFR
11 activation of protein kinase activity GO:0032147 9.77 WNK1 MAP3K8 MAP2K7
12 positive regulation of epithelial cell proliferation GO:0050679 9.76 HRAS ERBB2 EGFR
13 positive regulation of protein phosphorylation GO:0001934 9.73 MTOR KRAS HRAS ERBB4 ERBB2 EGFR
14 cellular response to epidermal growth factor stimulus GO:0071364 9.71 ERBB4 ERBB2 EGFR
15 regulation of cell motility GO:2000145 9.67 ERBB4 ERBB3 ERBB2 EGFR
16 protein autophosphorylation GO:0046777 9.63 WNK1 MTOR ERBB4 ERBB2 EGFR AURKA
17 ERBB2 signaling pathway GO:0038128 9.62 ERBB4 ERBB3 ERBB2 EGFR
18 regulation of long-term neuronal synaptic plasticity GO:0048169 9.61 KRAS HRAS
19 response to osmotic stress GO:0006970 9.61 MAP2K7 EGFR
20 phosphorylation GO:0016310 9.61 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
21 response to isolation stress GO:0035900 9.59 KRAS HRAS
22 negative regulation of ERBB signaling pathway GO:1901185 9.58 ERBB2 EGFR
23 protein phosphorylation GO:0006468 9.28 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3

Molecular functions related to Paronychia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.06 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
2 ATP binding GO:0005524 9.97 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
3 protein kinase binding GO:0019901 9.85 WNK1 MTOR MAP2K7 EGFR AURKA
4 protein serine/threonine kinase activity GO:0004674 9.83 WNK1 MTOR MAP3K8 MAP2K7 AURKA
5 kinase activity GO:0016301 9.81 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.67 ERBB4 ERBB3 ERBB2 EGFR
7 protein phosphatase binding GO:0019903 9.65 MAP2K7 ERBB2 EGFR
8 protein tyrosine kinase activity GO:0004713 9.65 MAP2K7 ERBB4 ERBB3 ERBB2 EGFR
9 nucleotide binding GO:0000166 9.56 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
10 protein kinase activity GO:0004672 9.28 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3

Sources for Paronychia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....